Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)

Sinil Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	8,529	4,643	7,519	4,944	7,340	4,163
Short-Term Investments	29,670	29,070	15,900	18,410	13,530	10,430
Cash & Short-Term Investments	38,199	33,713	23,419	23,354	20,870	14,593
Cash Growth	17.73%	43.96%	0.28%	11.90%	43.01%	7.44%
Accounts Receivable	19,598	20,248	21,878	23,420	20,588	20,910
Other Receivables	912.33	590.8	967.33	293.28	133.52	266.51
Receivables	20,510	20,839	22,845	23,713	20,721	21,192
Inventory	24,006	22,861	22,492	20,188	16,700	16,937
Prepaid Expenses	8.44	28.18	27.45	19.92	24.67	22.9
Other Current Assets	37.38	7.52	3.85	6.05	110.3	26.31
Total Current Assets	82,761	77,449	68,787	67,280	58,427	52,772
Property, Plant & Equipment	43,561	44,789	41,916	35,744	30,999	32,150
Long-Term Investments	798.27	726.62	839.01	966.42	1,512	1,509
Other Intangible Assets	1,680	1,736	1,810	1,870	1,801	1,320
Long-Term Accounts Receivable	0	-	-	-	-	-
Long-Term Deferred Tax Assets	2,600	2,413	2,097	1,944	1,804	2,510
Other Long-Term Assets	38,538	38,698	36,960	34,978	34,381	34,498
Total Assets	169,937	165,861	152,460	142,832	128,974	124,810
Accounts Payable	5,097	5,356	5,455	6,807	4,967	3,756
Accrued Expenses	972.89	897.01	901.59	824.11	734.16	877.02
Current Portion of Leases	145.7	164.45	165.01	135.5	133.75	125.94
Current Income Taxes Payable	1,086	2,161	267.59	2,105	486.48	572.36
Other Current Liabilities	7,411	7,875	7,355	6,088	5,702	5,055
Total Current Liabilities	14,711	16,453	14,145	15,959	12,023	10,387
Long-Term Leases	171.58	268.23	379.12	3.98	139.48	267.01
Pension & Post-Retirement Benefits	3,012	2,364	2,394	2,560	2,387	5,364
Other Long-Term Liabilities	334.71	270.53	646.79	1,031	1,228	1,308
Total Liabilities	18,230	19,356	17,565	19,554	15,777	17,326
Common Stock	5,993	5,993	5,993	5,771	5,609	5,451
Additional Paid-In Capital	1,170	1,170	1,170	1,170	1,170	1,170
Retained Earnings	145,645	140,444	128,688	117,118	106,663	100,940
Treasury Stock	-1,358	-1,358	-1,358	-1,285	-1,180	-1,012
Comprehensive Income & Other	256.8	256.8	402.28	503.25	934.27	934.27
Shareholders' Equity	151,707	146,506	134,895	123,277	113,196	107,484
Total Liabilities & Equity	169,937	165,861	152,460	142,832	128,974	124,810
Total Debt	317.28	432.68	544.13	139.48	273.22	392.95
Net Cash (Debt)	37,882	33,281	22,875	23,214	20,597	14,200
Net Cash Growth	18.47%	45.49%	-1.46%	12.71%	45.04%	8.67%
Net Cash Per Share	-	2879.07	1978.43	2086.88	1832.18	1261.79
Filing Date Shares Outstanding	-	11.56	11.56	11.12	11.24	11.25
Total Common Shares Outstanding	-	11.56	11.56	11.12	11.24	11.25
Working Capital	68,050	60,996	54,643	51,321	46,403	42,386
Book Value Per Share	-	12673.99	11669.56	11082.32	10069.36	9550.53
Tangible Book Value	150,028	144,769	133,085	121,407	111,395	106,164
Tangible Book Value Per Share	-	12523.79	11512.97	10914.20	9909.14	9433.25
Land	2,094	2,094	2,094	2,094	2,094	2,094
Buildings	38,238	36,456	34,193	28,429	19,865	19,643
Machinery	54,175	50,582	47,680	17,654	6,877	7,885
Construction In Progress	-	3,056	125	4,994	1,463	1,534

Source: S&P Global Market Intelligence. Standard template. Financial Sources.